Transforming growth factor beta 1 level in differentiated thyroid tumors, metastases and blood plasma

Background. One of the most important tasks facing endocrine surgery is the determination of reliable markers of metastasis in the treatment of papillary thyroid carcinoma (PTC). Markers that can be determined at the stage of preoperative research are of particular value. Transforming growth factor...

Full description

Saved in:
Bibliographic Details
Main Authors: N.Ya. Kobrynska, V.M. Pushkarev, N.I. Levchuk, O.I. Kovzun, I.I. Komisarenko, B.B. Guda, M.D. Tronko
Format: Article
Language:English
Published: Zaslavsky O.Yu. 2025-06-01
Series:Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:
Online Access:https://iej.zaslavsky.com.ua/index.php/journal/article/view/1560
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849711634579193856
author N.Ya. Kobrynska
V.M. Pushkarev
N.I. Levchuk
O.I. Kovzun
I.I. Komisarenko
B.B. Guda
M.D. Tronko
author_facet N.Ya. Kobrynska
V.M. Pushkarev
N.I. Levchuk
O.I. Kovzun
I.I. Komisarenko
B.B. Guda
M.D. Tronko
author_sort N.Ya. Kobrynska
collection DOAJ
description Background. One of the most important tasks facing endocrine surgery is the determination of reliable markers of metastasis in the treatment of papillary thyroid carcinoma (PTC). Markers that can be determined at the stage of preoperative research are of particular value. Transforming growth factor β1 (TGF-β1) can be one of these markers. The aim of the study was to compare the levels of TGF-β1 in tissue samples of follicular adenoma, goiter, PTC, metastases, and conditionally normal tissue. Materials and methods. Postoperative samples of tissue and blood plasma obtained from the surgical department of the V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU clinic were used for research. The amount of TGF-β1 was determined using enzyme immunoassay kits. Results. The level of TGF-β1 in the tissue of follicular adenoma and nodular goiter exceeded the levels in conditionally normal tissue by approximately 2 times. There was significant difference from conditionally normal tissue in РТС tissues without metastases. The concentration of TGF-β1 in the tumor tissue of РТС with metastases was higher than in the conditionally normal tissue by almost 5 times and by 3 times higher than in РТС tissues without metastases. It is important to note that the level of TGF-β1 in metastases was higher than in the adenoma and goiter tissue but did not differ from tumor tissue of РТС without metastases. In blood plasma of patients with PTC without metastases, the concentration of TGF-β1 significantly exceeded that in controls, but did not differ from patients with PTC and metastases. Conclusions. Our data indicate significant differences in the concentration of TGF-β1 between tumor tissues of PTC with and without metastasis. In blood plasma of patients with PTC without metastases, TGF-β1 level exceeded that in controls, but did not differ from patients with PTC and metastases.
format Article
id doaj-art-34cc2b1a65bf48cf930f860ade70e00b
institution DOAJ
issn 2224-0721
2307-1427
language English
publishDate 2025-06-01
publisher Zaslavsky O.Yu.
record_format Article
series Mìžnarodnij Endokrinologìčnij Žurnal
spelling doaj-art-34cc2b1a65bf48cf930f860ade70e00b2025-08-20T03:14:35ZengZaslavsky O.Yu.Mìžnarodnij Endokrinologìčnij Žurnal2224-07212307-14272025-06-0121436436710.22141/2224-0721.21.4.2025.15601558Transforming growth factor beta 1 level in differentiated thyroid tumors, metastases and blood plasmaN.Ya. Kobrynska0https://orcid.org/0000-0001-8698-9793V.M. Pushkarev1https://orcid.org/0000-0003-0347-7771N.I. Levchuk2https://orcid.org/0000-0003-0482-5176O.I. Kovzun3https://orcid.org/0000-0002-6906-6636I.I. Komisarenko4https://orcid.org/0000-0002-1808-667XB.B. Guda5https://orcid.org/0000-0002-9181-0679M.D. Tronko6https://orcid.org/0000-0001-7421-0981V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, UkraineV.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, UkraineV.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, UkraineV.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, UkraineV.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, UkraineV.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, UkraineV.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, UkraineBackground. One of the most important tasks facing endocrine surgery is the determination of reliable markers of metastasis in the treatment of papillary thyroid carcinoma (PTC). Markers that can be determined at the stage of preoperative research are of particular value. Transforming growth factor β1 (TGF-β1) can be one of these markers. The aim of the study was to compare the levels of TGF-β1 in tissue samples of follicular adenoma, goiter, PTC, metastases, and conditionally normal tissue. Materials and methods. Postoperative samples of tissue and blood plasma obtained from the surgical department of the V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU clinic were used for research. The amount of TGF-β1 was determined using enzyme immunoassay kits. Results. The level of TGF-β1 in the tissue of follicular adenoma and nodular goiter exceeded the levels in conditionally normal tissue by approximately 2 times. There was significant difference from conditionally normal tissue in РТС tissues without metastases. The concentration of TGF-β1 in the tumor tissue of РТС with metastases was higher than in the conditionally normal tissue by almost 5 times and by 3 times higher than in РТС tissues without metastases. It is important to note that the level of TGF-β1 in metastases was higher than in the adenoma and goiter tissue but did not differ from tumor tissue of РТС without metastases. In blood plasma of patients with PTC without metastases, the concentration of TGF-β1 significantly exceeded that in controls, but did not differ from patients with PTC and metastases. Conclusions. Our data indicate significant differences in the concentration of TGF-β1 between tumor tissues of PTC with and without metastasis. In blood plasma of patients with PTC without metastases, TGF-β1 level exceeded that in controls, but did not differ from patients with PTC and metastases.https://iej.zaslavsky.com.ua/index.php/journal/article/view/1560papillary thyroid carcinomametastasistransforming growth factor β1
spellingShingle N.Ya. Kobrynska
V.M. Pushkarev
N.I. Levchuk
O.I. Kovzun
I.I. Komisarenko
B.B. Guda
M.D. Tronko
Transforming growth factor beta 1 level in differentiated thyroid tumors, metastases and blood plasma
Mìžnarodnij Endokrinologìčnij Žurnal
papillary thyroid carcinoma
metastasis
transforming growth factor β1
title Transforming growth factor beta 1 level in differentiated thyroid tumors, metastases and blood plasma
title_full Transforming growth factor beta 1 level in differentiated thyroid tumors, metastases and blood plasma
title_fullStr Transforming growth factor beta 1 level in differentiated thyroid tumors, metastases and blood plasma
title_full_unstemmed Transforming growth factor beta 1 level in differentiated thyroid tumors, metastases and blood plasma
title_short Transforming growth factor beta 1 level in differentiated thyroid tumors, metastases and blood plasma
title_sort transforming growth factor beta 1 level in differentiated thyroid tumors metastases and blood plasma
topic papillary thyroid carcinoma
metastasis
transforming growth factor β1
url https://iej.zaslavsky.com.ua/index.php/journal/article/view/1560
work_keys_str_mv AT nyakobrynska transforminggrowthfactorbeta1levelindifferentiatedthyroidtumorsmetastasesandbloodplasma
AT vmpushkarev transforminggrowthfactorbeta1levelindifferentiatedthyroidtumorsmetastasesandbloodplasma
AT nilevchuk transforminggrowthfactorbeta1levelindifferentiatedthyroidtumorsmetastasesandbloodplasma
AT oikovzun transforminggrowthfactorbeta1levelindifferentiatedthyroidtumorsmetastasesandbloodplasma
AT iikomisarenko transforminggrowthfactorbeta1levelindifferentiatedthyroidtumorsmetastasesandbloodplasma
AT bbguda transforminggrowthfactorbeta1levelindifferentiatedthyroidtumorsmetastasesandbloodplasma
AT mdtronko transforminggrowthfactorbeta1levelindifferentiatedthyroidtumorsmetastasesandbloodplasma